DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function

BACKGROUND: Coronavirus-associated acute respiratory distress syndrome (CARDS) has limited effective therapy to date. NLRP3 inflammasome activation induced by SARS-CoV-2 in COVID-19 contributes to cytokine storm. METHODS: This randomised, multinational study enrolled hospitalised patients (18–80 yea...

Descripción completa

Detalles Bibliográficos
Autores principales: Madurka, Ildiko, Vishnevsky, Alexander, Soriano, Joan B., Gans, Stephanus J., Ore, Danilo Joel Salazar, Rendon, Adrian, Ulrik, Charlotte S., Bhatnagar, Sushma, Krishnamurthy, Srikanth, Mc Harry, Kirsten, Welte, Tobias, Fernandez, Alberto A., Mehes, Beata, Meiser, Karin, Gatlik, Ewa, Sommer, Ulrike, Junge, Guido, Rezende, Ederlon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9473473/
https://www.ncbi.nlm.nih.gov/pubmed/36104613
http://dx.doi.org/10.1007/s15010-022-01904-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9473473/
https://www.ncbi.nlm.nih.gov/pubmed/36104613
http://dx.doi.org/10.1007/s15010-022-01904-w

Ejemplares similares